ROLONTIS Trademark

Trademark Overview

On Wednesday, December 7, 2016, a trademark application was filed for ROLONTIS with the United States Patent and Trademark Office. The USPTO has given the ROLONTIS trademark a serial number of 87260340. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, September 20, 2024. This trademark is owned by Spectrum Pharmaceuticals, Inc.. The ROLONTIS trademark is filed in the Pharmaceutical Products category with the following description:

PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF CANCER AND RELATED SYMPTOMS; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF NEUTROPENIA
rolontis

General Information

Serial Number87260340
Word MarkROLONTIS
Filing DateWednesday, December 7, 2016
Status710 - CANCELLED - SECTION 8
Status DateFriday, September 20, 2024
Registration Number5419341
Registration DateTuesday, March 6, 2018
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 25, 2017

Trademark Statements

Goods and ServicesPHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF CANCER AND RELATED SYMPTOMS; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF NEUTROPENIA

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, September 20, 2024
Primary Code005
First Use Anywhere DateThursday, December 14, 2017
First Use In Commerce DateThursday, December 14, 2017

Trademark Owner History

Party NameSpectrum Pharmaceuticals, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressLake Forest, IL 60045
Party NameSpectrum Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressHenderson, NV 89052
Party NameSpectrum Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressHenderson, NV 89052

Trademark Events

Event DateEvent Description
Thursday, March 16, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, December 10, 2016NEW APPLICATION ENTERED
Monday, December 12, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, March 10, 2017ASSIGNED TO EXAMINER
Wednesday, April 5, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 25, 2017PUBLISHED FOR OPPOSITION
Tuesday, April 25, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, June 21, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, December 18, 2017TEAS STATEMENT OF USE RECEIVED
Monday, December 18, 2017USE AMENDMENT FILED
Thursday, January 4, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, January 4, 2018STATEMENT OF USE PROCESSING COMPLETE
Saturday, January 27, 2018ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, January 30, 2018NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, March 6, 2018REGISTERED-PRINCIPAL REGISTER
Tuesday, October 4, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, October 4, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, October 4, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, October 4, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, October 4, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, March 6, 2023COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Wednesday, January 17, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, January 17, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, January 17, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, September 20, 2024CANCELLED SEC. 8 (6-YR)
Wednesday, January 17, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, January 17, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

Related Keywords

rolontis pharmaceutical treatment preparations neutropenia symptoms cancer prevention related